What Did STAR*D Teach Us? Results From a Large-Scale, Practical, Clinical Trial for Patients With Depression
The DOI matches its Crossref record.
Abstract
The authors provide an overview of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study (www.star-d.org), a large-scale practical clinical trial to determine which of several treatments are the most effective "next-steps" for patients with major depressive disorder whose symptoms do not remit or who cannot tolerate an initial treatment and, if needed, ensuing treatments. Entry criteria were broadly defined and inclusive, and patients were enrolled from psychiatric and primary care clinics. All participants began on citalopram and were managed by clinic physicians, who followed an algorithm-guided acute-phase treatment through five visits over 12 weeks. At the end of each sequence, patients whose depression had not fully remitted were eligible for subsequent randomized trials in a sequence of up to three clinical trials. In general, remission rates in the study clinics were lower than expected, suggesting the need for several steps to achieve remission for most patients. There was no clear medication "winner" for patients whose depression did not remit after one or more aggressive medication trials. Both switching and augmenting appeared to be reasonable options when an initial antidepressant treatment failed, although these two strategies could not be directly compared. Further, the likelihood of remission after two vigorous medication trials substantially decreased, and remission would likely require more complicated medication regimens for which the existing evidence base is quite thin. STAR*D demonstrated that inclusion of more real-world patients in clinical trials is both feasible and informative. Policy implications of the findings, as well as the study's limitations, are discussed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“low efficacy (only 27% of depressed patients achieved remission after 12 weeks of citalopram treatment as measured by HAM-D)”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [259]
In the citing paper
“the current standard of care treatments suffer from slow onset (e.g., 7 week average response time with citalopram)”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [259]
In the citing paper
“Studies examining antidepressant efficacy reveal 30% of depressed patients fail to respond to common antidepressant treatment (1)”
From Emerging Role for Nucleus Accumbens Medium Spiny Neuron Subtypes in Depression (2017) · cites this paper as [1]
In the citing paper
“Currently available antidepressant medications, alone and in combination, are associated with high rates of partial- or non-response, delayed response onset of weeks to months, and limited duration of efficacy5.”
From Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants (2016) · cites this paper as [5]
In the citing paper
“while more than a third fail to achieve remission even after several rounds of treatment ( Al-Harbi, 2012 , Gaynes et al., 2009 , Strawbridge et al., 2022 )”
From Self-blame-selective hyper-connectivity between anterior temporal and subgenual cortices predicts prognosis in major depressive disorder (2023) · cites this paper as Gaynes et al., 2009
Citations
Cites
Still being checked.
Cited by
Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants
Duman, R. S., Aghajanian, G. K., Sanacora, G., & Krystal, J. H. (2016) · Nature Medicine · doi:10.1038/nm.4050 · Cited by 1,750
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301
Major depressive disorder: new clinical, neurobiological, and treatment perspectives
Kupfer, D. J., Frank, E., & Phillips, M. L. (2012) · The Lancet · doi:10.1016/s0140-6736(11)60602-8 · Cited by 894
Depression: A cognitive perspective
LeMoult, J., & Gotlib, I. H. (2019) · Clinical Psychology Review · doi:10.1016/j.cpr.2018.06.008 · Cited by 792
Bauer, M., Pfennig, A., Severus, E., Whybrow, P. C., Angst, J., Möller, H.-J., & Šon behalf of the Task Force on Unipolar Depressive Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.804195 · Cited by 632
“%) than during the last two (10 – 20%, Gaynes et al. 2009).”
BackgroundToward a Neuroimaging Treatment Selection Biomarker for Major Depressive Disorder
McGrath, C. L., Kelley, M. E., Holtzheimer, P. E., Dunlop, B. W., Craighead, W. E., Franco, A. R., Craddock, R. C., & Mayberg, H. S. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.143 · Cited by 561
Singh, J. B., Fedgchin, M., Daly, E., Xi, L., Melman, C., De Bruecker, G., Tadic, A., Sienaert, P., Wiegand, F., Manji, H., et al. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.10.018 · Cited by 466
Depression in the Primary Care Setting
Park, L. T., & Zarate, C. A. (2019) · New England Journal of Medicine · doi:10.1056/nejmcp1712493 · Cited by 458
Biomarkers for depression: recent insights, current challenges and future prospects
Strawbridge, R., Young, A. H., & Cleare, A. J. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s114542 · Cited by 415
“improving response to treatments for depression Despite an extensive range of treatment options for major depression, only approximately a third of patients with MDD achieve remission even when receiving optimal antidepressant treatment according to consensus guidelines and using measurement-based care, and rates of t…”
BackgroundRapid-acting glutamatergic antidepressants: the path to ketamine and beyond
Krystal, J. H., Sanacora, G., & Duman, R. S. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.03.026 · Cited by 406
Fee, C., Banasr, M., & Sibille, E. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.05.024 · Cited by 329
Overview of glutamatergic neurotransmission in the nervous system
Niciu, M. J., Kelmendi, B., & Sanacora, G. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.08.008 · Cited by 329
Interferon-Induced Depression in Chronic Hepatitis C: A Systematic Review and Meta-Analysis
Udina, M., Castellví, P., Moreno-España, J., Navinés, R., Valdés, M., Forns, X., Langohr, K., Solà, R., Vieta, E., & Martín-Santos, R. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12r07694 · Cited by 297
The heterogeneity of the depressive syndrome: when numbers get serious
Østergaard, S. D., Jensen, S. O. W., & Bech, P. (2011) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2011.01744.x · Cited by 287
Wagner, K. M., McReynolds, C. B., Schmidt, W. K., & Hammock, B. D. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.06.006 · Cited by 270
Depression in neurodegenerative diseases: Common mechanisms and current treatment options
Galts, C. P. C., Bettio, L. E. B., Jewett, D. C., Yang, C. C., Brocardo, P. S., Rodrigues, A. L. S., Thacker, J. S., & Gil-Mohapel, J. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.04.002 · Cited by 269
An excitatory synapse hypothesis of depression
Thompson, S. M., Kallarackal, A. J., Kvarta, M. D., Van Dyke, A. M., LeGates, T. A., & Cai, X. (2015) · Trends in Neurosciences · doi:10.1016/j.tins.2015.03.003 · Cited by 265
Krystal, J. H., Davis, L. L., Neylan, T. C., A. Raskind, M., Schnurr, P. P., Stein, M. B., Vessicchio, J., Shiner, B., Gleason, T. D., & Huang, G. D. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.03.007 · Cited by 265
“The depression study, the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) may be particularly informative in its design (63-65), as many of the medications and treatment strategies for PTSD derive from those developed for depression.”
MethodKetamine and rapid antidepressant action: New treatments and novel synaptic signaling mechanisms
Krystal, J. H., Kavalali, E. T., & Monteggia, L. M. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01629-w · Cited by 262
“…initial antidepressant, modest incremental bene fi ts were seen with subsequent treatments, approximately one-third of patients remained unremitted after four treatments, and the one-year relapse rate among patients with treatment-resistant symptoms (Steps 3 and 4) was approximately 75% [7, 8].”
BackgroundKetamine for Treatment-Resistant Unipolar Depression: Current Evidence
Mathew, S. J., Shah, A., Lapidus, K., Clark, C., Jarun, N., Ostermeyer, B., & Murrough, J. W. (2012) · CNS Drugs · doi:10.2165/11599770-000000000-00000 · Cited by 238
Emerging Role for Nucleus Accumbens Medium Spiny Neuron Subtypes in Depression
Francis, T. C., & Lobo, M. K. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.09.007 · Cited by 230
“Studies examining antidepressant efficacy reveal 30% of depressed patients fail to respond to common antidepressant treatment (1), suggesting a need for new targeted therapies.”
BackgroundSex differences in antidepressant efficacy
LeGates, T. A., Kvarta, M. D., & Thompson, S. M. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-018-0156-z · Cited by 230
Ho, C. S. H., Lim, L. J. H., Lim, A. Q., Chan, N. H. C., Tan, R. S., Lee, S. H., & Ho, R. C. M. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00378 · Cited by 221
“Furthermore, the probability of treatment response seems to decrease with each new treatment option (8).”
BackgroundDe Carlo, V., Calati, R., & Serretti, A. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.04.034 · Cited by 217
Personalized brain circuit scores identify clinically distinct biotypes in depression and anxiety
Tozzi, L., Zhang, X., Pines, A., Olmsted, A. M., Zhai, E. S., Anene, E. T., Chesnut, M., Holt-Gosselin, B., Chang, S., Stetz, P. C., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03057-9 · Cited by 212
Pharmacological approaches to the challenge of treatment-resistant depression
Ionescu, D. F., Rosenbaum, J. F., & Alpert, J. E. (2015) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2015.17.2/dionescu · Cited by 212
Issues for DSM-5: Whither Melancholia? The Case for Its Classification as a Distinct Mood Disorder
Parker, G., Fink, M., Shorter, E., Taylor, M. A., Akiskal, H., Berrios, G., Bolwig, T., Brown, W. A., Carroll, B., Healy, D., et al. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09101525 · Cited by 211
Su, T.-P., Chen, M.-H., Li, C.-T., Lin, W.-C., Hong, C.-J., Gueorguieva, R., Tu, P.-C., Bai, Y.-M., Cheng, C.-M., & Krystal, J. H. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.94 · Cited by 209
Differences between opioids: pharmacological, experimental, clinical and economical perspectives
Drewes, A. M., Jensen, R. D., Nielsen, L. M., Droney, J., Christrup, L. L., Arendt‐Nielsen, L., Riley, J., & Dahan, A. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04317.x · Cited by 208
Clinical Use of Curcumin in Depression: A Meta-Analysis
Ng, Q. X., Koh, S. S. H., Chan, H. W., & Ho, C. Y. X. (2017) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2016.12.071 · Cited by 200
Peripheral Markers of Depression
Nobis, A., Zalewski, D., & Waszkiewicz, N. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9123793 · Cited by 197
Psychiatric Disorders: Diagnosis to Therapy
Krystal, J. H., & State, M. W. (2014) · Cell · doi:10.1016/j.cell.2014.02.042 · Cited by 190
Circulating myeloid-derived MMP8 in stress susceptibility and depression
Cathomas, F., Lin, H.-Y., Chan, K. L., Li, L., Parise, L. F., Alvarez, J., Durand-de Cuttoli, R., Aubry, A. V., Muhareb, S., Desland, F., et al. (2024) · Nature · doi:10.1038/s41586-023-07015-2 · Cited by 189
Gene × Environment Interactions: From Molecular Mechanisms to Behavior
Halldorsdottir, T., & Binder, E. B. (2017) · Annual Review of Psychology · doi:10.1146/annurev-psych-010416-044053 · Cited by 188
Rosenblat, J. D., & McIntyre, R. S. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.10.042 · Cited by 178
Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder
Niciu, M. J., Ionescu, D. F., Richards, E. M., & Zarate, C. A. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-013-1130-x · Cited by 155
Psychedelics and Other Psychoplastogens for Treating Mental Illness.
Vargas, M. V., Meyer, R., Avanes, A. A., Rus, M., & Olson, D. E. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.727117 · Cited by 166
Glutamate and GABA Homeostasis and Neurometabolism in Major Depressive Disorder
Sarawagi, A., Soni, N. D., & Patel, A. B. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.637863 · Cited by 165
Fabbri, C., Hagenaars, S. P., John, C., Williams, A. T., Shrine, N., Moles, L., Hanscombe, K. B., Serretti, A., Shepherd, D. J., Free, R. C., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01062-9 · Cited by 162
Nowak, W., Grendas, L. N., Sanmarco, L. M., Estecho, I. G., Arena, Á. R., Eberhardt, N., Rodante, D. E., Aoki, M. P., Daray, F. M., Carrera Silva, E. A., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.10.063 · Cited by 159
“One third of patients with MDD did not achieve remission despite multiple trials using different types of antidepressants [22].”
BackgroundMolecular and Cellular Mechanisms of Rapid-Acting Antidepressants Ketamine and Scopolamine
Wohleb, E. S., Gerhard, D., Thomas, A., & Duman, R. S. (2017) · Current Neuropharmacology · doi:10.2174/1570159x14666160309114549 · Cited by 148
Pehrson, A. L., Cremers, T., Bétry, C., van der Hart, M. G. C., Jørgensen, L., Madsen, M., Haddjeri, N., Ebert, B., & Sanchez, C. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.04.006 · Cited by 155
Kubitz, N., Mehra, M., Potluri, R. C., Garg, N., & Cossrow, N. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076882 · Cited by 143
Rosenblat, J. D., Lee, Y., & McIntyre, R. S. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.08.056 · Cited by 135
Brain Structural Effects of Antidepressant Treatment in Major Depression
Dusi, N., Barlati, S., Vita, A., & Brambilla, P. (2015) · Current Neuropharmacology · doi:10.2174/1570159x1304150831121909 · Cited by 131
Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status
Henter, I. D., Park, L. T., & Zarate, C. A. (2021) · CNS Drugs · doi:10.1007/s40263-021-00816-x · Cited by 142
“inhibitors [SSRIs] and serotonin-norepinephrine reuptake inhibitors [SNRIs], among others) initially revolutionized the treatment of depression, these treatments are not effective for all individuals with MDD [2].”
BackgroundAn adaptationist perspective on the etiology of depression
Durisko, Z., Mulsant, B. H., & Andrews, P. W. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.09.032 · Cited by 140
The Depression Treatment Cascade in Primary Care: A Public Health Perspective
Pence, B. W., O’Donnell, J. K., & Gaynes, B. N. (2012) · Current Psychiatry Reports · doi:10.1007/s11920-012-0274-y · Cited by 133
“In STAR*D, a study of over 4,000 patients that defined the relative benefit of different depression treatment strategies for a “real world” clinical population with multiple medical and psychiatric comorbidities, approximately one-third of participants achieved remission after 12 weeks of treatment with a first antide…”
BackgroundSelf-citationRosson, S., de Filippis, R., Croatto, G., Collantoni, E., Pallottino, S., Guinart, D., Brunoni, A. R., Dell’Osso, B. M., Pigato, G., Hyde, J., et al. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104743 · Cited by 133
Enneking, V., Leehr, E. J., Dannlowski, U., & Redlich, R. (2019) · Psychological Medicine · doi:10.1017/s0033291719003660 · Cited by 124
Carvalho, A. F., Berk, M., Hyphantis, T. N., & McIntyre, R. S. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000357500 · Cited by 123
Personalized machine learning of depressed mood using wearables
Shah, R. V., Grennan, G., Zafar-Khan, M., Alim, F., Dey, S., Ramanathan, D., & Mishra, J. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01445-0 · Cited by 123
Fischell, J., Van Dyke, A. M., Kvarta, M. D., LeGates, T. A., & Thompson, S. M. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.112 · Cited by 122
Ketamine as a promising prototype for a new generation of rapid‐acting antidepressants
Abdallah, C. G., Averill, L. A., & Krystal, J. H. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12718 · Cited by 121
Fabbri, C., Tansey, K. E., Perlis, R. H., Hauser, J., Henigsberg, N., Maier, W., Mors, O. N., Placentino, A., Rietschel, M., Souery, D., et al. (2018) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2018.05.009 · Cited by 120
Goetzl, E. J., Wolkowitz, O. M., Srihari, V. H., Reus, V. I., Goetzl, L., Kapogiannis, D., Heninger, G. R., & Mellon, S. H. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01268-x · Cited by 105
Widge, A. S., Ellard, K. K., Paulk, A. C., Basu, I., Yousefi, A., Zorowitz, S., Gilmour, A., Afzal, A., Deckersbach, T., Cash, S. S., et al. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2016.07.021 · Cited by 118
Gao, W., Wang, W., Peng, Y., & Deng, Z. (2019) · Metabolic Brain Disease · doi:10.1007/s11011-019-0389-5 · Cited by 117
Buckman, J. E. J., Saunders, R., Stott, J. C. H., Cohen, Z. D., Arundell, L.-L., Eley, T. C., Hollon, S. D., Kendrick, T., Ambler, G., Watkins, E. R., et al. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2022.0100 · Cited by 116
Ketamine’s effect on inflammation and kynurenine pathway in depression: A systematic review
Kopra, E., Mondelli, V., Pariante, C., & Nikkheslat, N. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211026426 · Cited by 97
Management of Depression in Parkinson's Disease: A Systematic Review
STARKSTEIN, S. E., & Brockman, S. (2017) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.12507 · Cited by 112
Depression Screening and Measurement-Based Care in Primary Care
Siniscalchi, K. A. S., Broome, M. E., Fish, J., Ventimiglia, J., Thompson, J. A., Roy, P., Pipes, R., & Trivedi, M. H. (2020) · Journal of Primary Care & Community Health · doi:10.1177/2150132720931261 · Cited by 110
Self-citationZanos, P., Nelson, M. E., Highland, J. N., Krimmel, S. R., Georgiou, P., Gould, T. D., & Thompson, S. M. (2017) · eNeuro · doi:10.1523/eneuro.0285-16.2017 · Cited by 106
Pharmacogenetics of antidepressant response: A polygenic approach
García‐González, J., Tansey, K. E., Hauser, J., Henigsberg, N., Maier, W., Mors, O. N., Placentino, A., Rietschel, M., Souery, D., Žagar, T., et al. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.01.011 · Cited by 106
Emerging role of the P2X7-NLRP3-IL1β pathway in mood disorders
Bhattacharya, A., & Jones, D. N. C. (2018) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2018.08.015 · Cited by 105
Chou, D., Peng, H.-Y., Lin, T.-B., Lai, C.-Y., Hsieh, M.-C., Wen, Y.-C., Lee, A.-S., Wang, H.-H., Yang, P.-S., Chen, G.-D., et al. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.06.033 · Cited by 104
Depression as a risk factor for adverse outcomes in coronary heart disease
Freedland, K. E., & Carney, R. M. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-131 · Cited by 87
Applications of blood-based protein biomarker strategies in the study of psychiatric disorders
Chan, M. K., Gottschalk, M. G., Haenisch, F., Tomasik, J., Ruland, T., Rahmoune, H., Guest, P. C., & Bahn, S. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2014.08.002 · Cited by 101
Erritzoe, D., Godlewska, B. R., Rizzo, G., Searle, G. E., Agnorelli, C., Lewis, Y., Ashok, A. H., Colasanti, A., Boura, I., Farrell, C., et al. (2023) · Biological Psychiatry · doi:10.1016/j.biopsych.2022.10.012 · Cited by 90
Kadriu, B., Greenwald, M., Henter, I. D., Gilbert, J. R., Kraus, C., Park, L. T., & Zarate, C. A. (2021) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa087 · Cited by 99
Wallace, A., Pehrson, A. L., Sánchez, C., & Morilak, D. A. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000571 · Cited by 97
“Clinical research suggests that only half of depressed patients respond to initial treatment with an SSRI, and only one-third eventually achieve remission (Gaynes et al., 2009).”
BackgroundHistory of Psychosurgery: A Psychiatrist's Perspective
Lapidus, K. A. B., Kopell, B. H., Ben‐Haim, S., Rezai, A. R., & Goodman, W. K. (2013) · World Neurosurgery · doi:10.1016/j.wneu.2013.02.053 · Cited by 97
Karim, H. T., Andreescu, C., Tudorascu, D., Smagula, S. F., Butters, M. A., Karp, J. F., Reynolds, C., & Aizenstein, H. J. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.55 · Cited by 95
Greenway, K. T., Garel, N., Jerome, L., & Feduccia, A. A. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1772054 · Cited by 94
“a norepinephrine-dopamine reuptake inhibitor (bupropion) [105].”
BackgroundLi, G., Fife, D., Wang, G., Sheehan, J. J., Bodén, R., Brandt, L., Brenner, P., Reutfors, J., & DiBernardo, A. (2019) · Annals of General Psychiatry · doi:10.1186/s12991-019-0248-0 · Cited by 83
Gill, H., Gill, B., Rodrigues, N. B., Lipsitz, O., Rosenblat, J. D., El-Halabi, S., Nasri, F., Mansur, R. B., Lee, Y., & McIntyre, R. S. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.11.020 · Cited by 93
Rosenblat, J. D., Simon, G. E., Sachs, G. S., Deetz, I., Doederlein, A., DePeralta, D., Dean, M. M., & McIntyre, R. S. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.09.027 · Cited by 92
Rapid antidepressant effect of ketamine correlates with astroglial plasticity in the hippocampus
Ardalan, M., Rafati, A. H., Nyengaard, J. R., & Wegener, G. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13714 · Cited by 92
Li, Y., Fan, C., Wang, L., Lan, T., Gao, R., Wang, W., & Yu, S. Y. (2021) · Journal of Clinical Investigation · doi:10.1172/jci148853 · Cited by 90
Krystal, J. H., Kaye, A. P., Jefferson, S., Girgenti, M. J., Wilkinson, S. T., Sanacora, G., & Esterlis, I. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2305772120 · Cited by 90
Philip, N. S., Dunner, D. L., Dowd, S. M., Aaronson, S. T., Brock, D. G., Carpenter, L. L., Demitrack, M. A., Hovav, S., Janicak, P. G., & George, M. S. (2016) · Brain Stimulation · doi:10.1016/j.brs.2015.11.007 · Cited by 79
A Review of the Conceptualisation and Risk Factors Associated with Treatment-Resistant Depression
Murphy, J. A., Sarris, J., & Byrne, G. J. (2017) · Depression Research and Treatment · doi:10.1155/2017/4176825 · Cited by 67
Molecular, Functional, and Structural Imaging of Major Depressive Disorder
Zhang, K., Zhu, Y., Zhu, Y., Wu, S., Liu, H., Zhang, W., Xu, C., Zhang, H., Hayashi, T., & Tian, M. (2016) · Neuroscience Bulletin · doi:10.1007/s12264-016-0030-0 · Cited by 88
Pharmacologic approaches to treatment resistant depression: a re-examination for the modern era
Philip, N. S., Carpenter, L. L., Tyrka, A. R., & Price, L. H. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656561003614781 · Cited by 70
Treating to target in major depressive disorder: response to remission to functional recovery
McIntyre, R. S., Lee, Y., & Mansur, R. B. (2015) · CNS Spectrums · doi:10.1017/s1092852915000826 · Cited by 84
Kvarta, M. D., Bradbrook, K. E., Dantrassy, H. M., Bailey, A. M., & Thompson, S. M. (2015) · Journal of Neurophysiology · doi:10.1152/jn.00359.2015 · Cited by 86
Sexual Dysfunction Due to Psychotropic Medications
Clayton, A. H., Alkis, A. R., Parikh, N., & Votta, J. G. (2016) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2016.04.006 · Cited by 86
Rachid, F. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2017.09.009 · Cited by 86
Cognition in major depressive disorder: a ‘Systemically Important Functional Index’ (SIFI)
McIntyre, R. S., & Lee, Y. (2016) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000221 · Cited by 85
Cognitive dysfunctions in depression – significance, description and treatment prospects
Czerwińska, A., & Pawłowski, T. (2020) · Psychiatria Polska · doi:10.12740/pp/onlinefirst/105415 · Cited by 85
Hexsel, D. M., Brum, C., Siega, C., Schilling-Souza, J., Forno, T. D., Heckmann, M., & Rodrigues, T. D. C. (2013) · Dermatologic Surgery · doi:10.1111/dsu.12175 · Cited by 85
Han, C., Wang, S., Bahk, W., Lee, S.-J., Patkar, A. A., Masand, P. S., Mandelli, L., Pae, C., & Serretti, A. (2018) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2018.16.4.469 · Cited by 85
Coenen, V. A., Schlaepfer, T. E., Sajonz, B., Döbrössy, M., Kaller, C. P., Urbach, H., & Reisert, M. (2020) · NeuroImage: Clinical · doi:10.1016/j.nicl.2020.102165 · Cited by 75
Rincón‐Cortés, M., & Grace, A. A. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.112367 · Cited by 80
Joffe, M. E., Santiago, C. I., Oliver, K. H., Maksymetz, J., Harris, N. A., Engers, J. L., Lindsley, C. W., Winder, D. G., & Conn, P. J. (2020) · Neuron · doi:10.1016/j.neuron.2019.09.044 · Cited by 76
Inflammation, stress and depression: An exploration of ketamine’s therapeutic profile
Johnston, J. N., Greenwald, M. S., Henter, I. D., Kraus, C., Mkrtchian, A., Clark, N. G., Park, L. T., Gold, P. W., Zarate, C. A., & Kadriu, B. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103518 · Cited by 79
Qin, T., Fang, F., Song, M., Li, R., Ma, Z., & Ma, S. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.09.039 · Cited by 79
Imaging the effect of ketamine on synaptic density (SV2A) in the living brain
Holmes, S. E., Finnema, S. J., Naganawa, M., DellaGioia, N., Holden, D., Fowles, K., Davis, M., Ropchan, J., Emory, P., Ye, Y., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01465-2 · Cited by 78
“Given the pervasive suffering and burden associated with major depressive disorder (MDD) and posttraumatic stress disorder (PTSD) [2], along with the limitations of traditional monoaminergic-based treatments in terms of efficacy and speed of action [3], the importance of this breakthrough cannot be overstated.”
BackgroundBiomarkers for Depression: Recent Insights, Current Challenges and Future Prospects
Strawbridge, R., Young, A. H., & Cleare, A. J. (2018) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.16206 · Cited by 78
Crane, N. A., Jenkins, L. M., Bhaumik, R., Dion, C., Gowins, J. R., Mickey, B. J., Zubieta, J.-K., & Langenecker, S. A. (2017) · Brain · doi:10.1093/brain/aww326 · Cited by 71
Metadata
- Authors
- Gaynes, B. N., Warden, D., Trivedi, M. H., Wisniewski, S. R., Fava, M., & Rush, A. J.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- The University of Texas Southwestern Medical Center (US)
- University of Pittsburgh (US)
- National University of Singapore (SG)
- Venue
- Psychiatric Services
- Published
- 2009-11
- Volume
- 60
- Issue
- 11
- Pages
- 1439-1445
- ISSN
- 0022-1597 (ISSN-L)
- 1075-2730
- 1557-9700
- OpenAlex
- W2095852687
- Cited by
- 661
- References
- 0
- Citations by year
- 2026: 37 · 2025: 47 · 2024: 57 · 2023: 73 · 2022: 61 · 2021: 58 · 2020: 55 · 2019: 48 · 2018: 41 · 2017: 42 · 2016: 28 · 2015: 33 · 2014: 20 · 2013: 20 · 2012: 16
- FWCI
- 9.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Psychiatric Services (publishedVersion, public-domain)
- PubMed (publishedVersion)
- Funders
- University of Texas Southwestern Medical Center
- National Institutes of Health (n01mh90003-26-0-0)
- National Institute of Mental Health (N01‐MH‐90003)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Keywords
- STAR*D, major depressive disorder, antidepressant treatment, treatment-resistant depression, remission, citalopram, antidepressant switching, antidepressant augmentation, primary care, psychiatric clinic
- MeSH terms
- Venlafaxine Hydrochloride, Adolescent, Adult, Aged, Cyclohexanols, Major Depressive Disorder, Female, Humans, Male, Middle Aged, Primidone, Remission Induction, Time Factors, Citalopram, Cognitive Behavioral Therapy, Bupropion, Treatment Outcome, Treatment Failure, Selective Serotonin Reuptake Inhibitors, Dopamine Uptake Inhibitors, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.